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Abstract
Objective—Laboratory monitoring is recommended during combination antiretroviral therapy
(cART), but the pattern of detected abnormalities and optimal monitoring are unknown. We
assessed laboratory abnormalities during initial cART in 2000–2010 across the United States.
Design—Observational study in the Centers for AIDS Research Network of Integrated Clinical
Systems Cohort.
Methods—Among patients with normal results within a year prior to cART initiation, time to
first significant abnormality was assessed by Kaplan–Meier curves stratified by event type, with
censoring at first of regimen change, loss to follow-up, or 104 weeks. Incidence rates of first
events were estimated using Poisson regression; multivariable analyses identified associated
factors. Results were stratified by time (16 weeks) from therapy initiation.
Results—A total of 3470 individuals contributed 3639 person-years. Median age, pre-cART
CD4, and follow-up duration were 40 years, 206 cells/μl, and 51 weeks, respectively. Incidence
rates for significant abnormalities (per 100 person-years) in the first 16 weeks post-cART
initiation were as follows: lipid 49 [95% confidence interval (CI) 41– 58]; hematologic = 44 (40–
49); hepatic = 24 (20–27); and renal = 9 (7–11), dropping substantially during weeks 17–104 of
cART to lipid = 23 (18–29); hematologic = 5 (4–6); hepatic = 6 (5–8); and renal = 2 (1–3) (all P <
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0.05). Among patients receiving initial cART with no prior abnormality (N = 1889), strongest
associations for hepatic abnormalities after 16 weeks were hepatitis B and C [hazard ratio 2.3
(95% CI 1.2–4.5) and hazard ratio = 3.0 (1.9–4.5), respectively]. The strongest association for
renal abnormalities was hypertension [hazard ratio = 2.8 (1.4–5.6)].
Conclusion—New abnormalities decreased after week 16 of cART. For abnormalities not
present by week 16, subsequent monitoring should be guided by comorbidities.
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Introduction
Adverse effects of combination antiretroviral therapy (cART) range from asymptomatic
laboratory abnormalities to life-threatening events. Although guidelines exist in the United
States for laboratory monitoring during cART [1], the optimal monitoring schedule to
balance patient safety and rational utilization of resources has not been determined. This
balance is necessary as healthcare resources are shrinking [2,3] while the number of patients
receiving cART is expected to increase as a result of new infections [4], intensified efforts to
identify and retain HIV-infected patients in care [5], and recommendation of cART in all
HIV-infected patients [6]. Further, studies in resource-limited settings have found no clinical
benefit to routine laboratoring monitoring for adverse effects during cART [7,8], possibly
with the exception of hemoglobin monitoring in those taking zidovudine (ZDV) [7].
HIV-infected persons are a heterogeneous population and a variety of antiretroviral drug
combinations are approved for initial cART [1]. Although it has been suggested that patient
and regimen differences may influence risk of specific adverse events [9–13], current
monitoring guidelines in the United States are largely the same regardless of patient
populations and regimens. This approach may lead to unnecessary monitoring for
uncommon adverse events in low-risk patients or inadequate monitoring for other adverse
events in patients with higher risk. Understanding the incidence and predictors of significant
laboratory abnormalities (i.e. those that require cART modification, further evaluation, or
direct treatment) is necessary to define optimal monitoring practices. We conducted this
study to determine the incidence and risk factors for significant hematologic, hepatic, renal,
and lipid abnormalities in patients who initiated cART in routine clinical care in the United
States between 2000 and 2010.
Methods
Study setting
This observational study was conducted using data from the Centers for AIDS Research
(CFAR) Network of Integrated Clinical Systems (CNICS) cohort. CNICS is a longitudinal
clinical cohort of HIV-infected patients receiving primary care from 1 January 1995 to the
present at eight medical centers across the United States, all affiliated with CFAR. The
CNICS cohort is diverse with regard to sex, race, ethnicity, age, HIV transmission risk
factors, and geographic distribution. The CNICS repository contains data from electronic
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medical record systems used to provide HIV care, and support clinical and translational HIV
research at the affiliated clinics [14].
Study population
The study population consisted of HIV-infected patients who were at least 18 years old;
initiated cARTat a CNICS site between 1 January 2000 and 31 January 2010; had a normal
result for their most recent laboratory test within a year prior to cART initiation based on the
definition of abnormalities used to evaluate outcomes; and had at least one laboratory
monitoring test result available after cART initiation while still receiving their initial cART
regimen. We considered hematologic, hepatic, renal, and lipid laboratory values post-cART
initiation and defined significant abnormalities as follows: hematologic = hemoglobin 10
g/dl or less, neutrophil count 750 cells/μl or less, or platelet count 50 × 109 cells/l or less;
hepatic = aspartate or alanine transaminase at least three times the upper limit of normal
(ULN) or direct bilirubin at least two times ULN; renal = estimated glomerular filtration rate
(eGFR) less than 50 ml/min per 1.73 m2. eGFR was calculated using the Modification of
Diet in Renal Disease (MDRD) formula [15]; a cut-off of less than 60 ml/min per 1.73 m2
was used in sensitivity analysis; and lipid abnormality = non-high-density lipo-protein
(HDL) cholesterol (i.e. total cholesterol minus HDL cholesterol) at least 160 mg/dl. Ethical
approval for CNICS was obtained from each site's Institutional Review Board, and for this
study from the University of North Carolina Institutional Review Board.
Combination antiretroviral therapy definition
To ensure that only regimens relevant to initial therapy in the modern cARTera were
considered, we defined cART as a regimen containing a ritonavir-boosted protease inhibitor,
nonnucleoside reverse transcriptase inhibitor (NNRTI), or integrase inhibitor along with at
least two nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Patients whose regimen
included didanosine, stavudine, nelfinavir, indinavir, unboosted protease inhibitor, or more
than two antiretroviral classes were excluded.
Statistical analysis
At-risk time for each patient began at cART initiation and ended at the first abnormality for
the laboratory index being evaluated, switch or discontinuation (for > 14 days) of any drug
in the regimen, loss to follow-up (≥ 12 months without a clinic visit or laboratory measure),
last clinic visit before 31 December 2010, or death. Follow-up was censored at 104 weeks
after cART initiation to ensure sufficient at-risk patients to obtain reliable estimates of
abnormality rates. Baseline characteristics at cART initiation were described and time to
first abnormality was estimated by the Kaplan–Meier method. Time to first abnormality was
calculated for each abnormality type. Overall incidence rates of first abnormalities and
incidence rates stratified by follow-up time were estimated using Poisson regression.
Hazard ratios were estimated to identify independent clinical and demographic predictors of
an incident laboratory abnormality using multivariable pooled logistic regression and
inverse-probability-of-frequency weights to account for differences in laboratory monitoring
frequency [16,17]. These weights were calculated using predicted probabilities of receiving
a laboratory test conditional on baseline covariates. The means for the weights were 1.09 for
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hematologic [standard deviation (SD) = 0.34, full range (range) = 0.33–2.50], 1.11 for
hepatic (SD = 0.36, range = 0.29–2.60), 1.12 for renal (SD = 0.37, range = 0.29–2.84), and
1.16 for lipid (SD = 0.53, range = 0.35–3.95). Multivariable analyses included all
demographic and clinical variables being evaluated as predictors as well as study site.
We evaluated the effect of time since cART initiation on the incidence of each laboratory
abnormality. Given substantial heterogeneity upon visual inspection of incidence rates
across time and formal statistical evaluation of changes in incidence rates, we report results
stratified by time from therapy initiation (0–16 and 17–104 weeks). For analyses evaluating
rates from 17– 104 weeks of cARTexposure by laboratory type, we only included patients
who remained on their initial cART through 16 weeks of therapy; and had at least one
normal value, and no abnormal values, for that laboratory type between 0 and 16 weeks
post-cART. In order to obtain measures of frequency for patients at differing levels of risk
after 16 weeks, Poisson regression was used to calculate incidence rates between 17 and 104
weeks within subgroups of patients defined by the strongest clinically meaningful predictors
identified in multivariable analyses. All analyses were conducted in SAS version 9.2 (SAS
Institute Inc., Cary, North Carolina, USA).
Results
Study population
The study population included 3470 patients who had at least one laboratory result following
cART initiation, including 3153, 3219, 3208, and 980 with at least one hematologic, hepatic,
renal, and lipid test, respectively. Patients without available pre-cART laboratory measures
or with documented pre-cART laboratory abnormalities were excluded (Fig. 1). The
population was 17.1% women, 36.3% black, and 43.8% white with a median age of 40 years
[interquartile range (IQR) 32–45] (Table 1). The median year of cART initiation was 2006
(IQR 2004–2008). At therapy initiation, the median CD4 cell count was 206 cells/μl (IQR
65–316) and the median log10 viral load was 4.9 copies/ml (IQR 4.4–5.4). The initial
regimens included an NNRTI (62.2%), mainly efavirenz (95.9% of NNRTIs); or a boosted
protease inhibitor (37.5%), most commonly atazanavir/ritonavir (56.0% of protease
inhibitors) or lopinavir/ritonavir (35.9% of protease inhibitors). Patient demographic and
clinical characteristics at cART initiation were similar across evaluated laboratory
abnormalities and follow-up time contributed.
The median time under observation was 51 weeks (IQR 19–104), yielding a total of 3639
person-years observed. Twenty-seven percent of patients remained on their first cART and
under observation for the full 104 weeks of follow-up, 34.4% changed their initial regimen
or had a regimen interruption, 18.3% were lost to follow-up, and 21.8% were censored on 31
December 2010 when follow-up ended. Patients had a median of 11 (IQR 5–18)
hematologic, nine (4–16) hepatic, four (2–7) renal, and two (1–4) lipid tests while on their
initial cART regimen.
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Incidence of first significant laboratory abnormalities
Over 104 weeks, a total of 867 patients experienced at least one hematologic, hepatic, renal,
or lipid abnormality, yielding an overall incidence rate of 33.8 per 100 person-years [95%
confidence interval (CI) 31.6–36.1]. Hematologic abnormalities (incidence rate of 15.2 per
100 person-years; 95% CI 13.9–16.7) were largely due to low hemoglobin (64.8% of total
abnormalities). The incidence rate for a hepatic abnormality was 11.0 per 100 person-years
(95% CI 9.9–12.2) and was driven by abnormal transaminases (75.8%). The incidence rate
for eGFR decline to less than 50 ml/min was 3.5 per 100 person-years (95% CI 2.9–4.3).
When we used an eGFR cut-off of less than 60 ml/min, the incidence rate was 7.8 (95% CI
6.8–8.8). Lipid abnormalities were the most frequent with an incidence rate of 32.1 per 100
person-years (95% CI 28.7–36.1; Table 2).
The cumulative probability of experiencing a laboratory abnormality by 104 weeks of
treatment was 17.7% for hematologic, 15.2% for hepatic, 5.1% for renal, and 41.9% for lipid
indices. Figure 2 illustrates that abnormalities were most common within the first 16 weeks.
As evident in Table 2, this elevated risk soon after cART initiation is particularly notable for
hematologic abnormalities, which were nine times more common in the first 16 weeks of
therapy compared with weeks 17– 104 (P < 0.001). Hepatic and renal events were four and
five times more frequent pre versus postweek 16 of therapy, respectively (both P < 0.001).
The drop in incidence rate after week 16 was less striking for lipid abnormalities, which
were approximately twice as frequent in the first 16 weeks (P < 0.001).
Predictors of first significant laboratory abnormalities
Female sex, African–American race, hepatitis B coin-fection, hypertension, boosted protease
inhibitor use, ZDV use, lower CD4 cell count, and AIDS diagnosis at cART initiation were
all independently predictive of a first hematologic abnormality during the first 104 weeks of
cART in multivariable analyses (Table 3). Analogous results were observed after restricting
to events occurring during the first 16 weeks of cARTuse. After 16 weeks of cART (among
those with no hematologic abnormality in first 16 weeks), boosted protease inhibitor use was
associated with a 1.8-fold increase in the incidence rate. CD4+ T-cell reconstitution during
cART predicted a lower hematologic abnormality rate; for each 50 CD4 cells/μl increase
from baseline to 16 weeks, there was an 11.5% relative reduction in the incidence rate.
These associations were not modified by ZDV use.
Lower CD4 cell count and AIDS diagnosis at cART initiation, other race (which included
Hispanic, Asian, American-Indian, and multiracial), boosted protease inhibitor use, and
coinfection with hepatitis B or C were associated with a higher rate of hepatic abnormality
during the total period of observation. Findings were similar when we considered the first 16
weeks of cART only. During weeks 17–104 of cART, hepatitis coinfections were most
strongly associated with hepatic abnormality with hepatitis B associated with more than
twice the rate of abnormalities, and hepatitis C associated with almost three times the rate
(Table 3). Boosted protease inhibitor use was associated with a 1.75-fold increase (95% CI
1.20–2.56). Next, we evaluated the absolute impact of these predictors on hepatic
abnormality rates. Patients coinfected with hepatitis B or C consistently experienced more
hepatic abnormalities; for example, 16 additional abnormalities per 100 person-years
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between 17 and 104 weeks of cART when compared to those without hepatitis B or C
coinfection (Table 4). Among patients with hepatitis coinfection, the rates of hepatic
abnormalities before and after week 16 were higher among those treated with boosted
protease inhibitors.
Decline in eGFR to less than 50 ml/min per 1.73 m2 during the first 104 weeks of cART was
most strongly associated with preexisting hypertension (Table 3). Other risk factors were
female sex, older age, lower CD4 cell counts, and boosted protease inhibitor use. Risk
factors were the same when restricting analyses to the first 16 weeks of cART. After 16
weeks, the strongest predictors of renal function decline were hypertension, female sex, and
greater increase in CD4 cell count. However, after 16 weeks, incidence rates were low even
in higher risk groups. For instance, patients with hypertension on a boosted protease
inhibitor-based regimen had an incidence rate of 5.9 (95% CI 3.4–10.3; Table 4). When we
changed the definition of significant renal abnormality to eGFR less than 60 ml/min per 1.73
m2, similar associations after 16 weeks were found, although older age and boosted protease
inhibitor use became the strongest predictors. African–American race was identified as an
additional independent predictor over the 104-week period using the less than 60 ml/min per
1.73 m2 cut-off (data not shown).
Lipid abnormalities within the first 16 weeks of cART were more common among patients
who were older, men, of non-African–American race, had an AIDS-defining illness, or were
hepatitis B and C negative. After 16 weeks post-cART initiation, no statistically significant
associations were identified (Table 3).
Discussion
We found that first significant hematologic, hepatic, renal, and lipid laboratory
abnormalities were most common in the early period (first 16 weeks) after initiating cART.
Among patients who remained on their initial regimen without abnormalities by week 16,
the incidence of subsequent laboratory abnormalities decreased substantially. Abnormalities
that occurred after week 16 (delayed abnormalities) were associated with pretreatment
comorbidities and cART regimen. Thus, hepatitis B or C coinfection were associated with
increased risk for delayed hepatic abnormalities, whereas hypertension was associated with
increased risk for delayed renal impairment. Compared to NNRTIs, boosted protease
inhibitor use was associated with increased risk of delayed hematologic, hepatic, and renal
abnormalities.
Although current guidelines recommend laboratory monitoring within 2–8 weeks of
initiating cART and then every 3–6 months afterwards in all patients [1], our findings
suggest that indefinite monitoring every 3–6 months without stratification by risk may not
be necessary in all patients. For example, long-term hepatic monitoring every 3–6 months
may be appropriate for hepatitis-coinfected patients because hepatitis B virus is associated
with over two-fold increased risk for delayed hepatic abnormalities and hepatitis C virus
(HCV) with approximately three-fold increased risk. In contrast, patients at relatively low
risk for delayed hepatic abnormalities (e.g. those not infected with hepatitis B or C) should
be considered for less frequent monitoring. We observed a low incidence of new renal
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abnormalities after 16 weeks, particularly in patients younger than 60 years without
hypertension, indicating that individuals in this subgroup may be candidates for less frequent
renal monitoring, although renal abnormalities may increase with longer duration of therapy.
Our findings are strengthened by the fact that many of the parameters that we identified as
risk factors for laboratory abnormalities are well established. A recent study noted higher
rates of hepatotoxicity among hepatitis B and/or C-coinfected patients receiving boosted
protease inhibitor regimens compared to those taking efavirenz-based regimens [18], a
finding corroborated in our study. Hypertension, a risk factor for renal abnormalities in the
current study, is a well known predictor of chronic kidney disease in both HIV-infected and
HIV-uninfected populations [19,20]. The hematologic side-effect profile of ZDV was well
described by the early 1990s [21], although a more recent study suggested a weaker link
between ZDV and anemia in the cART era [22]. In our study, ZDV use was associated with
hematologic abnormalities, but this effect extended only through the first 16 weeks of
therapy suggesting that ZDV use alone may not justify intensive hematologic monitoring
indefinitely. The observed higher rates of anemia among women and neutropenia in
African–Americans likely reflect lower baseline values in these subgroups [23,24]. Lipid
abnormalities were most common in the first 16 weeks in our study, which is consistent with
a large CNICS study that observed the greatest increase in lipid levels during the first 8
weeks of cART [25]. Of note, however, patients who have lipid levels measured within 4
months of therapy may represent a specific subpopulation that clinicians expect to have
higher risk for lipid abnormalities. Boosted protease inhibitor use was associated with renal
abnormalities, although an independent effect of tenofovir exposure on renal impairment
was not identified when we used an eGFR cut-off of 50 ml/min per 1.73 m2. It is possible
that detection of a tenofovir-specific effect on eGFR decline below 50 ml/ min per 1.73 m2
was hampered by the high prevalence of tenofovir use (73%). There are varying reports of
the associations between tenofovir and renal toxicity [10,26–30] and concomitant boosted
protease inhibitor exposure appears to heighten tenofovir toxicity risks [31]. There was an
unexpected independent association between boosted protease inhibitor use and hematologic
abnormalities, and an explanation for this association is not readily apparent.
This study is limited by the laboratory measurements available. Specifically, timing of the
measurements was variable given the real-world clinical care setting in which they were
obtained. However, we mitigated this limitation by incorporating inverse-probability-of-
frequency weights into the analysis to reduce the influence of patients who were tested more
frequently. Further, we did not have comprehensive data on HCV status of seropositive
patients; hence, some patients labeled with HCV infection on the basis of serologic testing
could have subsequently cleared their infection. This could have affected the precision of the
estimated impact of HCV. Also, although current guidelines recommend fasting lipids,
random lipid levels were obtained in many of patients; hence, we focused on non-HDL
cholesterol. Non-HDL cholesterol levels have an increasingly important role in
cardiovascular disease risk assessment and lipid-lowering treatment decisions [32],
particularly in the setting of elevated triglyceride levels, which is common among HIV-
infected individuals.
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Other factors should be considered when interpreting our study. First, only 36% of patients
evaluated in our study were in care and maintained on their initial cART regimen at week
104, reflecting challenges of patient retention [33] and switching to different regimens for a
variety of reasons. Further research will be needed to evaluate whether the associations we
identified extend beyond 2 years. Second, because we excluded patients with baseline
abnormalities for the laboratory type being evaluated and censored patient data after the first
laboratory abnormality of that type, this study does not address laboratory abnormalities
after an abnormal index value. Third, although our findings suggest that ritonavir-boosted
protease inhibitors may be associated with some increase in laboratory abnormalities when
compared to NNRTI-based regimens, this study was not designed to specifically assess
comparative safety of different regimens. We were unable to comprehensively address
issues such as dose of ritonavir, other agents (both antiretrovirals and non-antiretrovirals
coadministered), preexisting nonsignificant elevations in laboratory measures, and factors
that may predispose patients to receiving one type of cART regimen versus another. The
observational design of our study may have introduced other unmeasured confounding, but
we were able to utilize longitudinal comprehensive clinical data from a large number of
patients in routine care at diverse sites across the United States, making our results
generalizable. Frequently, results from randomized trials cannot be generalized to patients in
routine clinical care because of extensive inclusion and exclusion criteria that result in
enrolling individuals who may have a lower likelihood of adverse events [34]. Women
represented only 17% of the total population, the median duration of follow-up was
relatively short (51 weeks), and median pre-cART CD4 cell count was low (206 cells/μl).
Furthermore, only one measurement was available post-cART initiation for a proportion of
patients. Finally, there is increasing representation of persons older than 45 years in the HIV
population [4], a group at increased risk for age-associated noninfectious comorbidities and
polypharmacy [35]. A quarter of the patients in our study were over 45 years at ART
initiation, although the median age was 40 years.
Conclusion
In conclusion, among patients with normal laboratory indices at cART initiation, monitoring
for early laboratory abnormalities while asymptomatic appears justifiable in all patients
initiating cART. However, our findings suggest that long-term monitoring should vary
between patients and be informed by comorbidities and possibly cART regimen. If our
preliminary findings are confirmed and risk-guided monitoring is adopted, it would
represent a paradigm shift in the care of US HIV-infected patients with implications for
lifetime treatment costs and utilization of healthcare resources. Further work is indicated that
specifically focuses on comparative safety across regimens that are currently recommended
for initial cART. Future studies should also refine the parameters for risk stratification, the
optimal frequency of testing in high-risk and low-risk subgroups, and the cost–effectiveness
of risk-guided monitoring.
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Flow chart of exclusion criteria for patient population initiating combination antiretroviral
therapy in the Centers for AIDS Research Network of Integrated Clinical Systems, 2000–
2010. *Exclusions only apply to tests for the laboratory type under evaluation. cART,
combination antiretroviral therapy.
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Cumulative probability of laboratory abnormality following combination antiretroviral
therapy initiation stratified by laboratory type, Centers for AIDS Research Network of
Integrated Clinical Systems, 2000–2010. cART, combination antiretroviral therapy.
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Table 1
Demographic and clinical characteristics of patients initiating combination antiretroviral therapy, Centers for




    Male 2875 (82.9)
    Female 595 (17.1)
Race/ethnicity
    African–American 1258 (36.3)
    Whites 1520 (43.8)




CD4 cell count (cells/μl)
b 206 (65–316)
HIV RNA (log10 copies/ml)
b 4.9 (4.4–5.4)
cART regimen type
    Boosted PI 1300 (37.5)
        Atazanavir 728 (56.0)
        Lopinavir/ritonavir 467 (35.9)
        Darunavir 69 (5.3)
        Fosamprenavir 36 (2.8)
    NNRTI 2164 (62.4)
        Efavirenz 2075 (60.0)
        Nevirapine 89 (2.6)
    Other
c 6 (0.2)
        Raltegravir 2 (0.1)
        Maraviroc 4 (0.1)
ZDV in regimen 751 (21.6)
TDF in regimen 2518 (72.6)
ABC in regimen 357 (10.3)
ABC, abacavir; cART, combination antiretroviral treatment; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; TDF, tenofovir; ZDV, zidovudine.
a
Other includes Hispanic, Asian, American-Indian, multiracial, or other race.
b
Median (IQR) given instead of N (%).
c
Other includes integrase inhibitor or entry inhibitor regimens.
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Table 2
Incident laboratory abnormalities over first 2 years following combination antiretroviral therapy initiation,
Centers for AIDS Research Network of Integrated Clinical Systems, 2000–2010.
IR per 100 person-years (95% CI)
Laboratory parameter
a Patients Abnormal results Person-years 0–104 weeks 0–16 weeks 17–104 weeks
b
Hematologic 3153 445 2930 15.2 (13.9–16.7) 43.9 (39.5–48.9) 4.9 (4.0–6.0)
Hepatic 3219 330 3009 11.0 (9.9–12.2) 23.5 (20.4–27.0) 6.2 (5.2–7.5)
Renal 3208 112 3175 3.5 (2.9–4.3) 8.6 (6.9–10.9) 1.8 (1.3–2.5)
Lipid 980 291 908 32.1 (28.7–36.1) 48.9 (41.1–58.1) 22.7 (17.9–28.8)
CI, confidence interval; HDL, high-density lipoprotein; IR, incidence rate.
a
Hematologic measures include 14 591 hemoglobin tests, 12 848 neutrophil tests, and 15 207 platelet count tests; hepatic measures include 15 128
alanine aminotransferase tests, 15 128 aspartate aminotransferase tests, and 7435 direct bilirubin tests; renal measures include 19 733 creatinine
tests; lipid measures include 632 non-HDL cholesterol tests in a fasting state and 2429 non-HDL cholesterol in a nonfasting state.
b
Among those with a normal test of that laboratory type within the first 16 weeks.
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Table 3
Independent predictors of laboratory abnormalities following combination antiretroviral therapy initiation,









N = 3153 N = 3153 N = 1889
Age (by decade increase) 1.06 (0.94–1.20) 1.04 (0.90–1.20) 1.07 (0.86–1.34)
Female sex 1.66 (1.27–2.16) 1.61 (1.16–2.22) 1.78 (1.09–2.92)
Race/ethnicity
    Whites Ref. Ref. Ref.
    African–American 1.69 (1.28–2.22) 1.39 (1.00–1.93) 2.68 (1.59–4.52)
    Other 1.35 (0.97–1.87) 1.29 (0.87–1.91) 1.51 (0.81–2.83)
CD4 cell count (by 100 cells/μl increase) 0.72 (0.66–0.79) 0.67 (0.59–0.75) 0.87 (0.75–1.01)
AIDS diagnosis 1.38 (1.07–1.77) 1.56 (1.16–2.10) 1.15 (0.70–1.89)
Boosted PI regimen (compared to NNRTI)
c 1.27 (1.00–1.61) 1.11 (0.83–1.48) 1.80 (1.15–2.81)
ZDV use 1.78 (1.39- 2.28) 1.84 (1.38–2.47) 1.43 (0.86–2.39)
Hepatitis B 1.64 (1.06–2.53) 1.61 (0.97–2.69) 1.72 (0.75–3.93)
Hepatitis C 1.23 (0.90–1.68) 1.12 (0.77–1.65) 1.50 (0.84–2.66)
Hypertension 1.35 (1.03–1.76) 1.27 (0.91–1.77) 1.40 (0.86–2.26)
CD4 cell count change (by 50cells/μl increase)
d – – 0.89 (0.80–0.99)
Viral load suppression (<400 copies/ml)
d – – 0.68 (0.41–1.12)
Hepatic
N = 3219 N = 3219 N = 1957
Age (by decade increase) 1.01 (0.88–1.15) 0.82 (0.67–1.01) 1.24 (1.01–1.52)
Female sex 0.94 (0.68–1.31) 1.04 (0.65–1.67) 0.87 (0.52–1.47)
Race/ethnicity
    Whites Ref. Ref. Ref.
    African–American 1.03 (0.76–1.41) 1.02 (0.64–1.57) 0.88 (0.55–1.43)
    Other 1.36 (1.00–1.84) 1.26 (0.80–1.97) 1.46 (0.94–2.29)
CD4 cell count (by 100 cells/μl increase) 0.89 (0.82–0.97) 0.83 (0.73–0.94) 1.02 (0.91–1.14)
AIDS diagnosis 1.36 (1.03–1.79) 1.42 (0.96–2.11) 1.37 (0.89–2.08)
Boosted PI regimen (compared to NNRTI)
c 1.70 (1.32–2.19) 1.64 (1.13–2.37) 1.75 (1.20–2.56)
ZDV use 0.77 (0.53–1.11) 0.70 (0.42–1.18) 0.92 (0.53–1.60)
Hepatitis B 2.88 (1.93–4.30) 3.39 (1.98–5.81) 2.34 (1.22–4.47)
Hepatitis C 3.35 (2.55–4.41) 3.40 (2.28–5.05) 2.95 (1.94–4.48)
Hypertension 1.01 (0.75–1.35) 1.06 (0.68–1.64) 0.96 (0.62–1.49)
CD4 cell count change (by 50cells/μl increase)
d – – 0.94 (0.86–1.02)
Viral load suppression (<400 copies/ml)
d – – 0.83 (0.51–1.35)
Renal






























N = 3208 N = 3208 N = 2013
Age (by decade increase) 1.86 (1.50–2.32) 2.02 (1.51–2.70) 1.36 (0.96–1.93)
Female sex 1.86 (1.13–3.08) 1.59 (0.79–3.22) 3.08 (1.44–6.59)
Race/ethnicity
    Whites Ref. Ref. Ref.
    African–American 0.76 (0.46–1.26) 0.93 (0.45–1.93) 0.54 (0.25–1.15)
    Other 0.69 (0.36–1.35) 1.12 (0.49–2.55) 0.14 (0.03–0.73)
CD4 cell count (by 100cells/μl increase) 0.77 (0.65–0.91) 0.70 (0.54–0.90) 0.77 (0.61–0.96)
AIDS diagnosis 1.29 (0.79–2.10) 1.84 (0.95–3.55) 0.90 (0.40–2.04)
Boosted PI regimen (compared to NNRTI)
c 1.65 (1.06–2.55) 1.03 (0.55–1.92) 2.12 (1.07–4.23)
ZDV use 0.81 (0.45–1.46) 0.59 (0.24–1.45) 1.06 (0.45–2.48)
Hepatitis B 0.96 (0.33–2.78) 0.87 (0.19–3.91) 1.19 (0.26–5.54)
Hepatitis C 1.21 (0.71–2.06) 1.21 (0.58–2.50) 1.30 (0.55–3.04)
Hypertension 2.31 (1.48–3.61) 2.25 (1.21–4.20) 2.81 (1.41–5.59)
CD4 cell count change (by 50cells/μl increase)
d – – 0.79 (0.66–0.93)
Viral load suppression (<400 copies/ml)
d – – 0.59 (0.28–1.28)
Lipid
N = 980 N = 980 N = 308
Age (by decade increase) 1.30 (1.15–1.47) 1.30 (1.08–1.57) 0.99 (0.76–1.31)
Female sex 0.64 (0.44–0.94) 0.79 (0.44–1.41) 0.60 (0.26–1.39)
Race/ethnicity
    Whites Ref. Ref. Ref.
    African–American 0.69 (0.51–0.93) 0.54 (0.33–0.87) 0.77 (0.40–1.45)
    Other 1.17 (0.86–1.58) 0.95 (0.57–1.59) 1.87 (0.89–3.93)
CD4 cell count (by 100 cells/μl increase) 1.03 (0.96–1.11) 1.09 (0.98–1.23) 0.99 (0.83–1.18)
AIDS diagnosis 1.63 (1.24–2.16) 1.52 (0.96–2.39) 1.64 (0.89–3.01)
Boosted PI regimen (compared to NNRTI) 1.12 (0.87–1.43) 0.96 (0.64–1.45) 0.83 (0.47–1.47)
ZDV use 1.22 (0.92–1.62) 1.03 (0.65–1.65) 1.30 (0.64–2.66)
Hepatitis B 0.36 (0.15–0.91) 0.39 (0.09–1.65) 2.08 (0.47–9.18)
Hepatitis C 0.36 (0.22–0.58) 0.38 (0.17–0.83) 1.09 (0.46–2.59)
Hypertension 1.42 (1.06–1.88) 1.34 (0.86–2.08) 1.89 (0.93–3.86)
CD4 cell count change (by 50 cells/μl increase)
d – – 1.02 (0.90–1.14)
Viral load suppression (<400 copies/ml)
d – – 0.60 (0.30–1.22)
Underlined associations are those with 95% confidence intervals that do not overlap 1.0. aHR, adjusted hazard ratio; CI, confidence interval;
NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ZDV, zidovudine.
a
All models adjusted for other covariates listed and study site.
b
Among those with a normal test of that laboratory type within the first 16 weeks.
c
Associations were different for atazanavir/ritonavir and lopinavir/ritonavir for some of the abnormalities in the first 16 weeks; both boosted PIs
were associated with higher incidence of hematologic, hepatic, and renal toxicities after 16 weeks compared to NNRTI use (data not shown).
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d
CD4 cell count change was evaluated as the difference between the baseline measure and the most recent measure before week 16. Viral load
suppression was evaluated based on most recent measure before week 16. Both of these covariates were only included in regression analysis for
predicting laboratory abnormalities after week 16.
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Table 4
Rates of laboratory abnormalities between 17 and 104 weeks following combination antiretroviral therapy
initiation stratified by select patient demographic and clinical characteristics, Centers for AIDS Research
Network of Integrated Clinical Systems, 2000–2010.
Incidence rate per 100 person-years (95% CI)
Abnormality type and subgroup 0–16 weeks 17–104 weeks
Hepatic total 23.5 (20.4–27.0) 6.2 (5.2–7.5)
    Neither hepatitis B or C 15.9 (13.1–19.2) 4.2 (3.3–5.2)
    Either hepatitis B or C 60.1 (48.5–74.4) 20.2 (15.4–26.5)
    NNRTI-based regimen with neither hepatitis B or C 12.2 (9.6–15.5) 3.2 (2.4–4.2)
    PI-based regimen with neither hepatitis B or C 43.2 (32.8–56.8) 6.2 (4.6–8.3)
    NNRTI-based regimen with either hepatitis B or C 22.7 (17.9–28.7) 14.4 (10.2–20.3)
    PI-based regimen with either hepatitis B or C 80.3 (62.8–103.5) 28.4 (20.8–38.7)
Renal total 8.6 (6.9–10.9) 1.8 (1.3–2.5)
    Age <60 years without hypertension 6.6 (4.9–8.9) 1.3 (0.8–1.9)
    Age ≥60 years or with hypertension 15.8 (11.0–22.7) 3.6 (2.2–5.8)
    NNRTI-based regimen without hypertension 5.5 (3.8–8.0) 0.9 (0.5–1.5)
    PI-based regimen without hypertension 8.2 (5.5–12.1) 1.9 (1.1–3.2)
    NNRTI-based regimen with hypertension 14.3 (9.3–21.9) 2.8 (1.5–5.0)
    PI-based regimen with hypertension 21.2 (13.7–32.6) 5.9 (3.4–10.3)
CI, confidence interval; IR, incidence rate; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ZDV, zidovudine.
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